Wird geladen...
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
Pirfenidone is a pleiotropic molecule approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone has demonstrated to downregulate transforming growth factor-β1 (TGF-β1) cellular effects. However, its anti-fibrotic mechanism remains unclear. Here, we aim to analyze the effects of pirfenidone...
Gespeichert in:
| Veröffentlicht in: | Oncotarget |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Impact Journals LLC
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7170494/ https://ncbi.nlm.nih.gov/pubmed/32341751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27526 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|